BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24930385)

  • 1. Expression and activity levels of matrix metalloproteinase-7 and in situ localization of caseinolytic activity in colorectal cancer.
    Keles D; Arslan B; Terzi C; Tekmen I; Dursun E; Altungoz O; Oktay G
    Clin Biochem; 2014 Sep; 47(13-14):1265-71. PubMed ID: 24930385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases.
    Zeng ZS; Shu WP; Cohen AM; Guillem JG
    Clin Cancer Res; 2002 Jan; 8(1):144-8. PubMed ID: 11801551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.
    Horiuchi S; Yamamoto H; Min Y; Adachi Y; Itoh F; Imai K
    J Pathol; 2003 Aug; 200(5):568-76. PubMed ID: 12898592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer.
    Oshima T; Akaike M; Yoshihara K; Shiozawa M; Yamamoto N; Sato T; Yamada R; Fujii S; Rino Y; Kunisaki C; Tanaka K; Masuda M; Imada T
    Oncol Rep; 2008 Aug; 20(2):359-64. PubMed ID: 18636198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
    Nosho K; Yamamoto H; Taniguchi H; Adachi Y; Yoshida Y; Arimura Y; Endo T; Hinoda Y; Imai K
    Clin Cancer Res; 2004 Dec; 10(23):7950-7. PubMed ID: 15585629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
    Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
    Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of matrix metalloproteinase-7 mRNA expression in the invasive front and inner surface of tumor tissues in patients with colorectal cancer.
    Higashiguchi T; Hotta T; Takifuji K; Yokoyama S; Matsuda K; Tominaga T; Oku Y; Yamaue H
    Dis Colon Rectum; 2007 Oct; 50(10):1585-93. PubMed ID: 17676380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
    Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
    BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer.
    Oshima T; Kunisaki C; Yoshihara K; Yamada R; Yamamoto N; Sato T; Makino H; Yamagishi S; Nagano Y; Fujii S; Shiozawa M; Akaike M; Wada N; Rino Y; Masuda M; Tanaka K; Imada T
    Oncol Rep; 2008 May; 19(5):1285-91. PubMed ID: 18425389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer.
    Lubbe WJ; Zhou ZY; Fu W; Zuzga D; Schulz S; Fridman R; Muschel RJ; Waldman SA; Pitari GM
    Clin Cancer Res; 2006 Mar; 12(6):1876-82. PubMed ID: 16551873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases 2 and 9 in situ mRNA expression in colorectal tumors from Iraqi patients.
    Ahmed MM; Mohammed SH
    Indian J Pathol Microbiol; 2011; 54(1):7-14. PubMed ID: 21393869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
    Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
    Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma.
    Asano T; Tada M; Cheng S; Takemoto N; Kuramae T; Abe M; Takahashi O; Miyamoto M; Hamada J; Moriuchi T; Kondo S
    J Surg Res; 2008 May; 146(1):32-42. PubMed ID: 17543340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
    Määttä M; Soini Y; Liakka A; Autio-Harmainen H
    Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
    Cardillo MR; Di Silverio F; Gentile V
    Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
    Ishizaki T; Katsumata K; Tsuchida A; Wada T; Mori Y; Hisada M; Kawakita H; Aoki T
    Int J Mol Med; 2006 Feb; 17(2):357-62. PubMed ID: 16391837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of matrix metalloproteinase-1 in human colorectal carcinoma.
    Shiozawa J; Ito M; Nakayama T; Nakashima M; Kohno S; Sekine I
    Mod Pathol; 2000 Sep; 13(9):925-33. PubMed ID: 11007031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.